Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY: EW )

85.86 +0.77 (+0.90%)
Streaming Delayed Price Updated: 3:19 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Establishment Labs Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Establishment Labs stock cleared a key performance benchmark, with its Relative Strength Rating jumping to 92, up from 87 the day before. 
Via Investor's Business Daily
Inspire Medical Systems Stock Scores Relative Strength Rating Upgrade
Inspire Medical System stock reached an key technical benchmark, seeing its Relative Strength (RS) Rating jumping to 91. 
Via Investor's Business Daily
Five Of The Best Chinese Stocks To Keep An Eye On
This year has been a stellar one for the Chinese stock market. After a year that saw the Shanghai Stock 
Via Best Stocks
Pfizer Stock, Raytheon Lead 5 Stocks Near Buy Points
Pfizer, Raytheon lead stocks shielded from geopolitics and rate hikes. 
Via Investor's Business Daily
Expert Ratings for Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Upgrades 
Via Benzinga
Raytheon, Shell Lead Five Stocks Setting Up, Breaking Out From Strong Sectors
Raytheon and Shell are just below buy points. They have good company. 
Via Investor's Business Daily
7 Medical Device Stocks to Buy as Covid-19 Fears Fade
With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. 
Via InvestorPlace
3 Top S&P 500 Stock Market Gainers Today: Medicals Lead As This Sector Reverses Hard
Medical and gold stocks led the S&P 500. Transport stocks were big losers. 
Via Investor's Business Daily
FDA Approves Edwards Lifesciences' Resilia Valve For Mitral Replacement Surgery
The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) Mitris Resilia valve, a tissue valve replacement specifically designed for the heart's mitral... 
Via Benzinga
What 9 Analyst Ratings Have To Say About Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Where Edwards Lifesciences Stands With Analysts
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: 
Via Benzinga
Edwards Lifesciences Dips On Narrow Quarterly Miss, Light Outlook
Edwards issued light 2022 guidance after a fourth-quarter disappointment. 
Via Investor's Business Daily
Analyst Ratings For Edwards Lifesciences
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2022
Upgrades Bernstein upgraded the previous rating for Stryker Corp (NYSE:SYK) from Market Perform to Outperform. For the fourth quarter, Stryker had an EPS of $2.71, compared to... 
Via Benzinga
This Foreboding Sign Looms Over Edwards Lifesciences's Chart
If history is any guide, there may be trouble ahead for shares of Edwards Lifesciences (NYSE:EW). A so-called "death cross" has formed on its chart and, not surprisingly, this... 
Via Benzinga
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Stock Market Whipsaws Lower On Hawkish Fed, Tesla; Apple, Microsoft Earnings Strong: Weekly Review
Microsoft and Apple earnings were strong, but the correction is getting worse. 
Via Investor's Business Daily
Edwards Lifesciences Q4 Earnings Fall Short Of Expectations, Reaffirms FY22 Outlook
Heart device company Edwards Lifesciences Corp (NYSE: EW) posted Q4 adjusted EPS of $0.51, compared to $0.50 posted a year ago and below the consensus of $0.55.... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Reneo Pharmaceuticals (NASDAQ:RPHM 
Via Benzinga
Edwards Lifesciences: Q4 Earnings Insights
Edwards Lifesciences (NYSE:EW) reported its Q4 earnings results on Wednesday, January 26, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
5 Big Cap Earnings All Stars to Watch This Week
Some of these companies have perfect 5-year earnings surprise track records, even beating through the early months of the pandemic. It’s impressive. 
Via Talk Markets
Earnings Scheduled For January 26, 2022
Companies Reporting Before The Bell • Blue Foundry (NASDAQ:BLFY) is projected to report earnings for its fourth quarter. • First BanCorp (NYSE:FBP) is likely to... 
Via Benzinga
Preview: Edwards Lifesciences's Earnings
Edwards Lifesciences (NYSE:EW) is set to give its latest quarterly earnings report on Wednesday, 2022-01-26. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the... 
Via Benzinga
$100 Invested In This Stock 10 Years Ago, Would Be Worth This Much
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 10 years by 12.27% on an annualized basis. Buying $100 In EW: 10 years ago, an investor could have... 
Via Benzinga
Where Edwards Lifesciences Stands With Analysts
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW)... 
Via Benzinga
CNBC's Final Trades: Match Group, PayPal, Edwards Lifesciences And This Hospitality Major
On CNBC’s “Halftime Report Final ... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.